SG11201811237WA - Combination therapies - Google Patents

Combination therapies

Info

Publication number
SG11201811237WA
SG11201811237WA SG11201811237WA SG11201811237WA SG11201811237WA SG 11201811237W A SG11201811237W A SG 11201811237WA SG 11201811237W A SG11201811237W A SG 11201811237WA SG 11201811237W A SG11201811237W A SG 11201811237WA SG 11201811237W A SG11201811237W A SG 11201811237WA
Authority
SG
Singapore
Prior art keywords
international
a61k
gm
ma
pct
Prior art date
Application number
SG11201811237WA
Inventor
Jeffery Kutok
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201662354637P priority Critical
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Priority to PCT/US2017/038966 priority patent/WO2017223422A1/en
Publication of SG11201811237WA publication Critical patent/SG11201811237WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT Iiiimmomiolollmolommoolomoilloomommom (10) International Publication Number WO 2017/223422 Al (51) International Patent Classification: A61K 31/52 (2006.01) A61K 39/395 (2006.01) A61K 31/497 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/038966 (22) International Filing Date: 23 June 2017 (23.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/354,637 24 June 2016 (24.06.2016) US (71) Applicant: INFINITY PHARMACEUTICALS, INC. [US/US]; 780 Memorial Drive, Cambridge, MA 02139 (US). (72) Inventor: KUTOK, Jeffery, L.; 9 Oak Hill Road, Natick, MA 01760 (US). (74) Agent: BRUNER, Michael, J. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: COMBINATION THERAPIES Isobologram 1 None 1 1500 1 H9 I None 1 384 1 15u1 I GM I Z Factor I ATP Lite 172h I I I I I I I I I I I I I I I I I I I I I I 0 .5 1 Selinexor / .93uM FIG.1 (57) : Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceu- tically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a F1t3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer. [Continued on next page] WO 2017/223422 Al MIDEDIM0110101011101011100101101111001E0HOII11EHOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201811237WA 2016-06-24 2017-06-23 Combination therapies SG11201811237WA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201662354637P true 2016-06-24 2016-06-24
PCT/US2017/038966 WO2017223422A1 (en) 2016-06-24 2017-06-23 Combination therapies

Publications (1)

Publication Number Publication Date
SG11201811237WA true SG11201811237WA (en) 2019-01-30

Family

ID=59298529

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811237WA SG11201811237WA (en) 2016-06-24 2017-06-23 Combination therapies

Country Status (14)

Country Link
US (1) US20190216816A1 (en)
EP (1) EP3474856A1 (en)
JP (1) JP2019522657A (en)
KR (1) KR20190033526A (en)
CN (1) CN109640999A (en)
AU (1) AU2017281797A1 (en)
BR (1) BR112018077021A2 (en)
CA (1) CA3028718A1 (en)
CL (1) CL2018003700A1 (en)
IL (1) IL263680D0 (en)
MX (1) MX2018016227A (en)
PH (1) PH12018502652A1 (en)
SG (1) SG11201811237WA (en)
WO (1) WO2017223422A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190018408A (en) 2016-03-18 2019-02-22 이뮨 센서, 엘엘씨 Cyclic di-nucleotide compounds and methods of use

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381783D1 (en) 1982-03-03 1990-09-13 Genentech Inc Human antithrombin III, DNA sequences therefor, expression and cloning vectors contain such sequences and thus transformed cell cultures, to methods for expressing human antithrombin III and compositions containing them pharmaceutical.
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP4440344B2 (en) 1996-08-16 2010-03-24 シェーリング コーポレイションSchering Corporation Mammalian cell surface antigens; related reagents
JP2001520039A (en) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド Human tumor necrosis factor receptor-like protein, tr11, tr11sv1 and tr11sv2
JP2002502607A (en) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド Nucleic acids encoding novel tumor necrosis factor receptor homologue and it
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Anti-CTLA-4 human monoclonal antibodies
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP4994552B2 (en) 1999-09-16 2012-08-08 キュリス,インコーポレイテッド Hedgehog signaling pathway mediators, compositions and related uses
AT328002T (en) 1999-10-13 2006-06-15 Univ Johns Hopkins Med Connections for regulating the hedgehog-signal path, compositions and uses thereof
AU780612C (en) 1999-10-14 2005-10-20 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
IL133809D0 (en) 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
AU4966401A (en) 2000-03-30 2001-10-15 Curis Inc Small organic molecule regulators of cell proliferation
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US20030113828A1 (en) 2001-11-09 2003-06-19 Ginsberg Mark H. Compositions and methods for modulating Syk function
US20030232323A1 (en) 2001-11-13 2003-12-18 Wyeth Agents that modulate immune cell activation and methods of use thereof
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
WO2003088970A2 (en) 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
FR2850022B1 (en) 2003-01-22 2006-09-08 Centre Nat Rech Scient Novel use of mifepristone and its derivatives as modulators of the hedgehog protein signaling path and its applications
MXPA05012475A (en) 2003-05-23 2006-05-25 Wyeth Corp Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof.
JP2007524397A (en) 2003-07-03 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア Inhibition of SYK kinase expression
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
WO2005013800A2 (en) 2003-07-15 2005-02-17 The Johns Hopkins University Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005032343A2 (en) 2003-10-01 2005-04-14 The Johns Hopkins University Hedgehog signaling in prostate regeneration neoplasia and metastasis
US20080057071A1 (en) 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
WO2005049838A2 (en) 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp Compositions and methods to diagnose and treat lung cancer
US8057815B2 (en) 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
PL1745041T3 (en) 2004-04-30 2012-11-30 Genentech Inc Quinoxaline inhibitors of the hedgehog signalling pathway
JP2007537291A (en) 2004-05-13 2007-12-20 イコス・コーポレイションIcos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
KR101487481B1 (en) 2004-08-27 2015-01-28 인피니티 디스커버리, 인코포레이티드 Cyclopamine analogues and methods of use thereof
KR20150090263A (en) 2004-09-02 2015-08-05 제넨테크, 인크. Pyridyl inhibitors of hedgehog signalling
AU2005302279A1 (en) 2004-10-28 2006-05-11 Irm Llc Compounds and compositions as hedgehog pathway modulators
EP1854793A4 (en) 2005-02-28 2011-01-26 Japan Tobacco Inc NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY
JP5238936B2 (en) 2005-03-25 2013-07-17 ジーアイティーアール,インク.GITR, Inc. GITR binding molecules and uses thereof
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ME02260B (en) 2005-07-01 2016-02-29 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20090156611A1 (en) 2005-11-11 2009-06-18 Licentia Ltd. Mammalian hedgehog signaling modulators
WO2007059157A1 (en) 2005-11-14 2007-05-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
CN101405001A (en) 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 Methods of inhibiting BTK and SYK protein kinases
JP2009536156A (en) 2006-04-14 2009-10-08 ノバルティス アクチエンゲゼルシャフト Use of biaryl carboxamides in the treatment of hedgehog pathway related disorders
JO2883B1 (en) 2006-05-05 2015-03-15 اي ار ام ال ال سي Compounds And Compositions As Hedgehog Pathway Modulators
US20090306214A1 (en) 2006-05-09 2009-12-10 Eliahu Kaplan Use of Syk Tyrosine Kinase Inhibitors for the Treatment of Cell Proliferative Disorders
NZ576467A (en) 2006-10-31 2012-03-30 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
AU2007332493A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
AU2008222655B2 (en) 2007-03-07 2014-03-27 Infinity Pharmaceuticals, Inc. Cyclopamine lactam analogs and methods of use thereof
KR20090117957A (en) 2007-03-07 2009-11-16 인피니티 디스커버리, 인코포레이티드 Heterocyclic cyclopamine analogs and methods of use thereof
NZ579480A (en) 2007-03-14 2012-03-30 Exelixis Patent Co Llc 2-Arylamino-quinazoline derivatives
AU2008225766B2 (en) 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
WO2008131354A2 (en) 2007-04-20 2008-10-30 The Curators Of The University Of Missouri Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment
CN104945508B (en) 2007-06-18 2019-02-22 默沙东有限责任公司 For the antibody of people's programmed death receptor PD-1
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
CN101801413A (en) 2007-07-12 2010-08-11 托勒克斯股份有限公司 Combination therapies employing GITR binding molecules
NZ586121A (en) 2007-12-13 2012-03-30 Siena Biotech Spa Benzimidazole derivatives as hedgehog pathway antagonists and therapeutic applications thereof
JP5868596B2 (en) 2008-01-04 2016-02-24 インテリカイン, エルエルシー Specific chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101910081B (en) 2008-01-10 2012-10-10 旭硝子株式会社 Glass, coating material for light-emitting device, and light-emitting device
WO2009089598A2 (en) 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
FR2929851B1 (en) 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibiting a metabolic pathway involving the tyrosine kinase syk protein and method of identifying said molecules
EA019973B1 (en) 2008-04-16 2014-07-30 Портола Фармасьютиклз, Инк. INHIBITORS OF Syk PROTEIN KINASES
MX2011000039A (en) 2008-07-02 2011-05-31 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins.
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc human antibodies that bind to the gene 3 of lymphocyte activation (LAG-3) and uses these
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
JPWO2010030002A1 (en) 2008-09-12 2012-02-02 国立大学法人三重大学 Foreign GITR ligand expressing cells
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
KR20180129984A (en) 2008-09-26 2018-12-05 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010051550A1 (en) 2008-10-31 2010-05-06 University Of Rochester Methods of diagnosing and treating fibrosis
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
EP2373318B1 (en) 2008-12-08 2019-06-05 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
NZ592119A (en) 2008-12-09 2013-07-26 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
SG172943A1 (en) 2009-01-13 2011-08-29 Glaxo Group Ltd Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2010090723A2 (en) 2009-02-04 2010-08-12 University Of Georgia Research Foundation, Inc. Methods of inhibiting fibrogenesis and treating fibrotic disease
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille PD-1 antibody and PD-L1 antibody and use thereof
ES2632220T3 (en) 2009-06-15 2017-09-11 Rigel Pharmaceuticals, Inc. Small molecule tyrosine kinase inhibitors of the spleen (SYK)
TW201105669A (en) 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
US8722692B2 (en) 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
MX2012007154A (en) 2009-12-17 2012-08-01 Merck Sharp & Dohme Aminopyrimidines as syk inhibitors.
EP2516434B1 (en) 2009-12-23 2015-05-27 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
PL2519543T3 (en) 2009-12-29 2016-12-30 Heterodimer binding proteins and uses thereof
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP2013532153A (en) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
US20130195843A1 (en) 2010-06-23 2013-08-01 British Columbia Cancer Agency Branch Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806A2 (en) 2010-09-10 2018-01-30 Epizyme Inc human ezh2 inhibitors, and method of use thereof
CN103282352B (en) 2010-11-01 2016-08-10 波托拉医药品公司 Benzamides and nicotinamide as SYK regulator
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
EP2704571A4 (en) 2011-05-04 2014-10-29 Merck Sharp & Dohme Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101981873B1 (en) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 Anti-pd-l1 antibodies and uses thereof
CN104114576B (en) 2011-12-21 2017-04-05 诺华股份有限公司 The compositionss and method of the P factors are targeted for antibody
AR091649A1 (en) 2012-07-02 2015-02-18 Squibb Bristol Myers Co Optimization of antibodies that bind to the gene activation lymphocyte 3 (LAG-3) and their uses
CA2876995A1 (en) 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors
CA2890176A1 (en) 2012-11-02 2014-05-08 Tg Therapeutics, Inc. Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
JP6434416B2 (en) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー Pharmaceutical composition comprising a PDE4 inhibitor and a PI3δ inhibitor or a dual PI3δ-γ kinase inhibitor
WO2015160975A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
IL263680D0 (en) 2019-01-31
US20190216816A1 (en) 2019-07-18
JP2019522657A (en) 2019-08-15
CA3028718A1 (en) 2017-12-28
PH12018502652A1 (en) 2019-10-07
CL2018003700A1 (en) 2019-06-28
EP3474856A1 (en) 2019-05-01
WO2017223422A1 (en) 2017-12-28
BR112018077021A2 (en) 2019-04-02
MX2018016227A (en) 2019-07-08
AU2017281797A1 (en) 2019-01-24
CN109640999A (en) 2019-04-16
KR20190033526A (en) 2019-03-29

Similar Documents

Publication Publication Date Title
SG11201804807VA (en) Computer architecture and method for modifying data intake parameters based on a predictive model
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804711RA (en) Compounds and methods for kinase modulation, and indications therefor
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201809016QA (en) Selective interfacial mitigation of graphene defects
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201407200TA (en) Liquid formulation
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201804696RA (en) Techniques for metadata processing
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201408174UA (en) Antibody formulation
SG11201408261UA (en) Syringe
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201809082WA (en) Nlrp3 modulators